---

補一下看到的論文全文，然後隨手翻譯一下論文摘要，
至於全文歡迎自己點進去看。

Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of
an open‐label non‐randomized clinical trial
https://reurl.cc/MvZW1m

Patients and methods
French Confirmed COVID-19 patients were included in a single arm protocol
from early March to March 16th, to receive 600mg of hydroxychloroquine daily
and their viral load in nasopharyngeal swabs was tested daily in a hospital
setting. Depending on their clinical presentation, azithromycin was added to
the treatment. Untreated patients from another center and cases refusing the
protocol were included as negative controls. Presence and absence of virus at
Day6-post inclusion was considered the end point.

參與病患與研究方法



Results
Six patients were asymptomatic, 22 had upper respiratory tract infection
symptoms and eight had lower respiratory tract infection symptoms. Twenty
cases were treated in this study and showed a significant reduction of
the viral carriage at D6-post inclusion compared to controls, and much lower
average carrying duration than reported of untreated patients in the
literature. Azithromycin added to hydroxychloroquine was significantly more
efficient for virus elimination.

結果


Conclusion
Despite its small sample size our survey shows that hydroxychloroquine
treatment is significantly associated with viral load reduction/disappearance
in COVID-19 patients and its effect is reinforced by azithromycin.

結論
雖然本研究的樣本數較少，但仍顯示使用hydroxychloroquine治療患者，能顯著降低病毒
量或消滅病毒，且其效果會受到azithromycin的增強。

以上是研究摘要和翻譯，以下是我快速瀏覽研究後的想法。

一、人口學變項



不過似乎沒有紀錄抽菸狀況和慢性病病史這些風險因子，但男性較多、年齡較大的治療組
，推測這兩項應該也不會好到哪裡去。

二、時間



三、樣本數

如同結論所提到的，樣本數太少大概是這篇比較值得商榷的部分，這部分也只能等待更大
規模的臨床試驗。



另外，hydroxychloroquine和azithromycin是人類非常熟悉的藥物，劑型也是非常適合用
於廣泛控制的口服藥物，如果被證實有效，應該算是非常好的消息。

** French pharmaceutical Sanofi offers anti-malaria treatment for COVID-19 after
‘promising’ trials
https://www.arabnews.com/node/1643141/world

補充一下，非雙盲試驗這點應該影響很小，因為研究觀察的治療效果是病毒量，這種實驗
室檢查應該比較不會受到雙盲與否的影響。

--
--
※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 36.230.166.242 (臺灣)
※ 文章代碼(AID): #1USvvNt2 (nCoV2019)
※ 文章網址: https://www.ptt.cc/bbs/nCoV2019/M.1584635479.A.DC2.html